Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC.
Animals
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Cell Line, Tumor
Cell Proliferation
ErbB Receptors
/ genetics
Erlotinib Hydrochloride
/ analogs & derivatives
Halogenation
Humans
Liver
/ metabolism
Lung Neoplasms
/ diagnostic imaging
Mice, Inbred BALB C
Positron-Emission Tomography
Reference Standards
6-O-[18F]FEE
EGFR
Erlotinib
Fluorine-18
Imaging
NSCLC
PET
TKI
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
1
11
2018
medline:
12
5
2020
entrez:
1
11
2018
Statut:
ppublish
Résumé
Positron emission tomography (PET) using [ 6-O-Fluoroethylerlotinib (6-O-FEE) was synthesized and its anti-proliferative activity was tested using human NSCLC cell lines. The F-18-labeled compound, 6-O-[ In vitro, 6-O-FEE had maintained the selectivity and potency of erlotinib to EGFR 6-O-[
Identifiants
pubmed: 30377939
doi: 10.1007/s11307-018-1286-8
pii: 10.1007/s11307-018-1286-8
doi:
Substances chimiques
Erlotinib Hydrochloride
DA87705X9K
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
696-704Références
J Thorac Oncol. 2011 Jul;6(7):1287-9
pubmed: 21847041
Appl Radiat Isot. 2013 Aug;78:26-32
pubmed: 23665261
Clin Cancer Res. 2011 Mar 1;17(5):1169-80
pubmed: 21248300
J Thorac Oncol. 2017 Jul;12(7):e81-e84
pubmed: 28286242
EJNMMI Res. 2015 Feb 12;5:4
pubmed: 25853010
Oncotarget. 2016 Oct 11;7(41):66595-66605
pubmed: 27448974
Nucl Med Biol. 2017 Sep;52:7-15
pubmed: 28575795
Clin Cancer Res. 2013 Jan 1;19(1):183-93
pubmed: 23136193
J Thorac Oncol. 2016 Jul;11(7):946-63
pubmed: 27229180
J Thorac Oncol. 2013 Jul;8(7):823-59
pubmed: 23552377
Clin Cancer Res. 2015 Jul 15;21(14):3196-203
pubmed: 25829397
EJNMMI Res. 2016 Dec;6(1):10
pubmed: 26857779
J Clin Oncol. 2005 Apr 10;23(11):2493-501
pubmed: 15710947
Cancer Res. 2006 Aug 15;66(16):8163-71
pubmed: 16912195
Future Oncol. 2015;11(11):1611-23
pubmed: 26043215
Sci Rep. 2017 Jan 12;7:40374
pubmed: 28079142
Tumour Biol. 2012 Jun;33(3):607-15
pubmed: 22270450
JAMA Oncol. 2016 Aug 1;2(8):1014-22
pubmed: 27055085
J Clin Oncol. 2005 Sep 1;23(25):5900-9
pubmed: 16043828
EJNMMI Res. 2015 Mar 20;5:14
pubmed: 25853020
Cancer. 2018 Jan 15;124(2):248-261
pubmed: 29211297
Br J Cancer. 2011 Dec 6;105(12):1850-5
pubmed: 22095231
Lancet Oncol. 2009 May;10(5):432-3
pubmed: 19410185
Bioorg Med Chem Lett. 2018 Apr 1;28(6):1143-1148
pubmed: 29486966
Bioorg Med Chem Lett. 2017 Oct 1;27(19):4552-4557
pubmed: 28893469
Nucl Med Biol. 2017 Apr;47:56-61
pubmed: 28126682
Drug Discov Today. 2012 Nov;17(21-22):1175-87
pubmed: 22766374
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Nucl Med Biol. 1997 Feb;24(2):193-5
pubmed: 9089712
J Clin Oncol. 2017 Oct 20;35(30):3484-3515
pubmed: 28806116
Pharmacol Res. 2017 Mar;117:406-415
pubmed: 28089942
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
J Clin Oncol. 2011 May 20;29(15):2121-7
pubmed: 21482992
Cytotechnology. 1995 Feb;17(1):27-33
pubmed: 22359207
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6
pubmed: 27017476
Neoplasia. 2013 Dec;15(12):1347-53
pubmed: 24403856
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Micromachines (Basel). 2018 Feb 28;9(3):
pubmed: 30424034